{
    "id": "5c895cf0f9c2ba6b28000001",
    "question": "Have apolipoprotein mimetics been used in clinical trials?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to analyze the provided documents and look for any information related to apolipoprotein mimetics. Apolipoprotein mimetics are a class of drugs that mimic the function of apolipoproteins, which are proteins that bind to lipoproteins and play a crucial role in lipid metabolism. The documents provided do not specifically mention apolipoprotein mimetics, but we can infer that some of the drugs mentioned in the documents, such as mipomersen and lomitapide, target specific apolipoproteins (apo B-100 and apo B-48, respectively). However, these drugs are not typically classified as apolipoprotein mimetics. Therefore, we need to look for any information on apolipoprotein mimetics in the provided documents. After reviewing the documents, we found no mention of apolipoprotein mimetics in clinical trials. Hence, the answer is no.\", \"answer_choice\": \"B\"}",
    "snippets": [
        {
            "id": "Pharmacology_Katzung_3937",
            "title": "Pharmacology_Katzung",
            "content": "LaRosa JC et al: Safety and effect of very low levels of low density lipoprotein cholesterol on cardiovascular events. Am J Cardiol 2013;111:1221. Mampuya WM et al: Treatment strategies in patients with statin intolerance: The Cleveland Clinic experience. Am Heart J 2013;166:597. Nduka C et al: Impact of antiretroviral therapy on serum lipoprotein levels and dyslipidemias: a systematic review and meta-analysis. Int J Cardiol 2015;199:307. Perry CM: Lomitapide: A review of its use in adults with homozygous familial hypercholesterolemia. Am J Cardiovasc Drugs 2013;13:265. Raal FJ, Stein EA: The effects of mipomersen on inhibiting hepatic VLDL apolipoprotein B 100 and propensity for hepatic steatosis. Clin Chem 2016;62:1052. Reith C, Armitage J: Management of residual risk after statin therapy. Atherosclerosis 2016;245;161. Rodriguez F: Association between intensity of statin therapy and mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol 2016;2:47."
        },
        {
            "id": "Pharmacology_Katzung_3936",
            "title": "Pharmacology_Katzung",
            "content": "Elam M, Lovato E, Ginsberg H: The role of fibrates in cardiovascular disease prevention, The ACCORD\u2013lipid perspective. Curr Opin Lipidol 2011;22:55. Gaudet D et al: Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med 2015;373:438. Gouni-Berthold I et al: Systematic review of published phase 3 data on antiPCSK9 monoclonal antibodies in patients with hypercholesterolaemia. Br J Clin Pharmacol 2016;82:1412. International Atherosclerosis Society: IAS Position Paper: Global Recommendations for the Management of Dyslipidemia. Available at: www.athero.org/ IASPositionPaper.asp. Jacobson TA et al: On behalf of the NLA Expert Panel. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 2. J Clin Lipidol 2015;9:S1. LaRosa JC et al: Safety and effect of very low levels of low density lipoprotein cholesterol on cardiovascular events. Am J Cardiol 2013;111:1221."
        },
        {
            "id": "Biochemistry_Lippincott_790",
            "title": "Biochemistry_Lippinco",
            "content": "2. Apolipoproteins: The apolipoproteins associated with lipoprotein particles have a number of diverse functions, such as providing recognition sites for cell-surface receptors and serving as activators or coenzymes for enzymes involved in lipoprotein metabolism. Some of the apolipoproteins are required as essential structural components of the particles and cannot be removed (in fact, the particles cannot be produced without them), whereas others are transferred freely between lipoproteins. Apolipoproteins are divided by structure and function into several major classes, denoted by letters, with each class having subclasses (for example, apolipoprotein [apo] C-I, apo C-II, and apo CIII). [Note: The functions of all the apolipoproteins are not yet known.] B. Chylomicron metabolism"
        },
        {
            "id": "Pharmacology_Katzung_3875",
            "title": "Pharmacology_Katzung",
            "content": "Some individuals have combined heterozygosity for alleles producing nonfunctional and kinetically impaired receptors. In heterozygous patients, LDL can be normalized with reductase inhibitors or combined drug regimens (Figure 35\u20132). Homozygotes and those with combined heterozygosity whose receptors retain even minimal function may partially respond to niacin, ezetimibe, and reductase inhibitors. Emerging therapies for these patients include mipomersen, employing an antisense strategy targeted at apo B-100, and lomitapide, a small molecule inhibitor of microsomal triglyceride transfer protein (MTP), and monoclonal antibodies directed at PCSK9. LDL apheresis is effective in medication-refractory patients."
        },
        {
            "id": "InternalMed_Harrison_28140",
            "title": "InternalMed_Harrison",
            "content": "of apoB, either apoB-48 (chylomicron) or apoB-100 (VLDL, IDL, or LDL), is present on each lipoprotein particle. The human liver synthesizes apoB-100, and the intestine makes apoB-48, which is derived from the same gene by mRNA editing. HDLs have different apolipoproteins that define this lipoprotein class, most importantly apoA-I, which is synthesized in the liver and intestine and is found on virtually all HDL particles. ApoA-II is the second most abundant HDL apolipoprotein and is on approximately two-thirds of the HDL particles. ApoC-I, apoC-II, and apoC-III participate in the metabolism of triglyceride-rich lipoproteins. ApoE also plays a critical role in the metabolism and clearance of triglyceride-rich particles. Most apolipoproteins, other than apoB, exchange actively among lipoprotein particles in the blood. Apolipoprotein(a) [apo(a)] is a distinctive apolipoprotein and is discussed more below."
        },
        {
            "id": "Pharmacology_Katzung_3924",
            "title": "Pharmacology_Katzung",
            "content": "Development of inhibitors of proprotein convertase subtilisin/ kexin type 9 (PCSK9) followed on the observation that loss of function mutations result in very low levels of LDL and no apparent morbidity. Therapeutic agents currently available in this class are humanized antibodies to PCSK9 (evolocumab, alirocumab). LDL reductions of up to 70% at the highest doses have been achieved with these agents when administered subcutaneously every two weeks. (Evolocumab can also be given monthly at a higher dose). Triglycerides and apo B-100 are reduced, and Lp(a) levels decrease by about 25%. Rarely, hypersensitivity reactions have occurred. Local reactions at the injection site, upper respiratory and flu-like symptoms have been observed more frequently. Use of these agents is restricted to patients who have familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require additional reduction of LDL. They are given with diet and maximal tolerated statin and/or"
        },
        {
            "id": "Biochemistry_Lippincott_808",
            "title": "Biochemistry_Lippinco",
            "content": "E. High-density lipoprotein metabolism HDL comprise a heterogeneous family of lipoproteins with a complex metabolism that is not yet completely understood. HDL particles are formed in the blood by the addition of lipid to apo A-1, an apolipoprotein made and secreted by the liver and intestine. Apo A-1 accounts for ~70% of the apolipoproteins in HDL. HDL perform a number of important functions, including the following. 1. Apolipoprotein supply: HDL particles serve as a circulating reservoir of apo C-II (the apolipoprotein that is transferred to VLDL and chylomicrons and is an activator of LPL) and apo E (the apolipoprotein required for the receptor-mediated endocytosis of IDL and chylomicron remnants). 2."
        },
        {
            "id": "Pharmacology_Katzung_3850",
            "title": "Pharmacology_Katzung",
            "content": "Plasma lipids are transported in complexes called lipoproteins. Metabolic disorders that involve elevations in any lipoprotein species are termed hyperlipoproteinemias or hyperlipidemias. Hyperlipemia denotes increased levels of triglycerides. The major clinical sequelae of hyperlipidemias are acute pancreatitis and atherosclerosis. The former occurs in patients with marked hyperlipemia. Control of triglycerides can prevent recurrent attacks of this life-threatening disease. Atherosclerosis is the leading cause of death for both genders in the USA and other Western countries. Lipoproteins that contain apolipoprotein (apo) B-100 convey lipids into the artery wall. These are low-density (LDL), intermediate-density (IDL), very-low-density (VLDL), and lipoprotein(a) (Lp[a]). Remnant lipoproteins formed during the catabolism of chylomicrons that contain the B-48 protein (apo B-48) can also enter the artery wall, contributing to atherosclerosis."
        },
        {
            "id": "Pharmacology_Katzung_3852",
            "title": "Pharmacology_Katzung",
            "content": "Although treatment of hyperlipidemia can cause slow physical regression of plaques, the well-documented reduction in acute coronary events that follows vigorous lipid-lowering treatment is attributable chiefly to mitigation of the inflammatory activity of macrophages and is evident within 2\u20133 months after starting therapy. High-density lipoproteins (HDL) exert several antiatherogenic effects. They participate in retrieval of cholesterol from the artery wall and inhibit the oxidation of atherogenic lipoproteins. Low levels of HDL (hypoalphalipoproteinemia) are an independent risk factor for atherosclerotic disease and thus are a potential target for intervention."
        },
        {
            "id": "Pharmacology_Katzung_3876",
            "title": "Pharmacology_Katzung",
            "content": "Defects in the domain of apo B-100 that binds to the LDL receptor impair the endocytosis of LDL, leading to hypercholesterolemia of moderate severity. Tendon xanthomas may occur. Response to reductase inhibitors is variable. Upregulation of LDL receptors in liver increases endocytosis of LDL precursors but does not increase uptake of ligand-defective LDL particles. Fibrates or niacin may have beneficial effects by reducing VLDL production. B-100 B-100 VLDL LDL BloodR HepatocyteAcetyl-CoA HMG-CoA reductase inhibitors Cholesterol Bile acids Niacin GutResins Ezetimibe HMG-CoA FIGURE 35\u20132 Sites of action of HMG-CoA reductase inhibitors, niacin, ezetimibe, and resins used in treating hyperlipidemias. Low-density lipoprotein (LDL) receptors are increased by treatment with resins and HMG-CoA reductase inhibitors. VLDL, very-low-density lipoproteins; R, LDL receptor."
        },
        {
            "id": "Pharmacology_Katzung_3906",
            "title": "Pharmacology_Katzung",
            "content": "Skeletal muscle Fatty acid oxidation Lipoprotein lipase Endothelium Liver Apo Clll synthesis Apo Al and Apo AII synthesis Fatty acids VLDL, Chylomicron Transcription of LPL vessels Hydrolysis of VLDL and chylomicron triglycerides FIGURE 35\u20134 Hepatic and peripheral effects of fibrates. These effects are mediated by activation of peroxisome proliferator-activated receptor-\u03b1, which decreases the secretion of VLDL and increases its peripheral metabolism. LPL, lipoprotein lipase; VLDL, very-low-density lipoproteins. Niacin (but not niacinamide) decreases triglycerides and LDL levels, and Lp(a) in most patients. It often increases HDL levels significantly. Historically, combination therapy including niacin has been associated with regression of atherosclerotic coronary lesions in three angiographic trials and with extension of lifespan in one large trial in which patients received niacin alone."
        },
        {
            "id": "Pharmacology_Katzung_3865",
            "title": "Pharmacology_Katzung",
            "content": "TABLE 35\u20131 The primary hyperlipoproteinemias and their treatment. 1Single-drug therapy with marine omega-3 dietary supplement should be evaluated before drug combinations are used. 2Select pharmacologically compatible reductase inhibitor (see text). genetic data as well as ruling out secondary hyperlipidemias (Table 35\u20132). Phenotypes of abnormal lipoprotein distribution are described in this section. Drugs mentioned for use in these conditions are described in the following section on basic and clinical pharmacology. TABLE 35\u20132 Secondary causes of hyperlipoproteinemia."
        },
        {
            "id": "Pathology_Robbins_2258",
            "title": "Pathology_Robbins",
            "content": "Metabolic syndrome. Associated with central obesity (Chapter 8), this clinical entity is characterized by insulin resistance, hypertension, dyslipidemia (elevated triglycerides and depressed HDL), hypercoagulability, and a pro-inflammatory state, which may be triggered by cytokines released from adipocytes. The dyslipidemia, hyperglycemia, and hypertension are all cardiac risk factors, while the systemic hypercoagulabgramle and pro-inflammatory state may contribute to endothelial dysfunction and/or thrombosis. Lipoprotein(a) levels. Lipoprotein(a) is an LDL-like particle that contains apolipoprotein B-100 linked to apolipoprotein(a). Lipoprotein(a) levels are correlated with risk of coronary and cerebrovascular disease, independent of total cholesterol or LDL levels. Apolipoprotein(a) is homologous to plasminogen, suggesting a potential link between thrombogenesis and circulating molecules that can drive atherosclerosis."
        },
        {
            "id": "Pharmacology_Katzung_3933",
            "title": "Pharmacology_Katzung",
            "content": "Decreases catabolism of apoAI\u2022reducesVLDLsecretion from liver IncreasesHDL\u2022decreaseslipoprotein(a) [Lp(a)], LDL LowHDL\u2022elevatedVLDL,Lp(a); elevated LDL in statin-unresponsive or intolerant patients Oral\u2022largedoses\u2022Toxicity: Gastric irritation, flushing, low incidence of hepatic toxicity \u2022mayreduceglucosetolerance\u2022 Extended-release niacin: Similar to regular niacin \u2022 Sustained-release niacin (not the same as extended-release product): Should be avoided PCSK9 HUMANIZED MONOCLONAL ANTIBODIES Evolocumab Complexes PCSK9 Inhibits catabolism of LDL receptor Familial hypercholesterolemia not Parenteral\u2022Cost~$14,000/year\u2022Toxicity: injection site reactions, nasopharyngitis, responsive to oral therapy \u2022 Alirocumab Similar to evolucumab flu-like symptoms, rarely myalgia, neurocognitive and ophthalmologic events Atorvastatin Generic, Lipitor Cholestyramine Generic, Questran, Prevalite Colestipol Generic, Colestid Ezetimibe Generic, Zetia Fenofibrate Generic, Tricor, Antara, Lofibra"
        },
        {
            "id": "InternalMed_Harrison_28273",
            "title": "InternalMed_Harrison",
            "content": "Specialized druGS for HomozyGouS fH Two \u201corphan\u201d drugs are approved specifically for the management of homozygous FH. They include a small-molecule inhibitor of MTP, called lomitapide, and an antisense oligonucleotide against apoB, called mipomersen. These drugs reduce VLDL production and LDL-C levels in homozygous FH patients. Due to their mechanism of action, each drug causes an increase in hepatic fat, the long-term consequences of which are unknown. In addition, lomitapide is associated with gastrointestinal-related side effects, and mipomersen is associated with skin reactions and flu-like symptoms."
        },
        {
            "id": "Pharmacology_Katzung_3935",
            "title": "Pharmacology_Katzung",
            "content": "Boekholdt SM et al: Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: A meta-analysis. Circulation 2013;128:1504. Bonow RO, Yancy CW: High-intensity statins for secondary prevention. JAMA Cardiol 2017;2:55. Cannon CP et al: Ezetimibe added to statin therapy after acute coronary syndrome. N Engl J Med 2015;372:2387. Chou R et al: Statins for prevention of cardiovascular disease in adults: Evidence report and systematic review for the US Preventive Services Task Force. JAMA 2016;316:2008. Dron JS, Hegele RA: Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants. Curr Opin Lipidol 2017;28:161. Elam M, Lovato E, Ginsberg H: The role of fibrates in cardiovascular disease prevention, The ACCORD\u2013lipid perspective. Curr Opin Lipidol 2011;22:55."
        },
        {
            "id": "Biochemistry_Lippincott_816",
            "title": "Biochemistry_Lippinco",
            "content": "Lipoprotein (a), or Lp(a), is nearly identical in structure to an LDL particle. Its distinguishing feature is the presence of an additional apolipoprotein molecule, apo(a), which is covalently linked at a single site to apo B-100. Circulating levels of Lp(a) are determined primarily by genetics. However, factors such as diet may play some role, as trans FA have been reported to increase it. The physiologic function of Lp(a) is unknown. When present in large quantities in the plasma, Lp(a) is associated with an increased risk of coronary heart disease. [Note: Apo(a) is structurally homologous to plasminogen, the precursor of a blood protease whose target is fibrin, the main protein component of blood clots (see Chapter 35 online). It is hypothesized that elevated Lp(a) slows the breakdown of blood clots that trigger heart attacks because it competes with plasminogen for binding to fibrin.] Niacin reduces Lp(a), as well as LDL-C and TAG, and raises HDLC. VII. STEROID HORMONES"
        },
        {
            "id": "Physiology_Levy_3862",
            "title": "Physiology_Levy",
            "content": "of the remnant particles (ChyR, IDL, and LDL) can vary. In any case the LDL particle is a small, dense, cholesterol-rich particle that is potentially very atherogenic in the face of endothelial damage. LDL particles are safely imported into cells through the LDL receptor. It should be noted that in the conversion of IDL to LDL, the ApoE protein disassociates from the particle. This means that only receptors for which ApoB100 is a ligand can remove LDL from the blood. In contrast to the multiple ApoE receptors, only one receptor, the LDL receptor, can recognize and bind ApoB100. Thus loss or decrease of a functional LDL receptor has significant clinical consequences (see"
        },
        {
            "id": "Pharmacology_Katzung_3864",
            "title": "Pharmacology_Katzung",
            "content": "Lipoprotein disorders are detected by measuring lipids in serum after a 10-hour fast. Risk of heart disease increases with concentrations of the atherogenic lipoproteins, is inversely related to levels of HDL-C, and is modified by other risk factors. Evidence from clinical trials suggests that an LDL cholesterol (LDL-C) level of 50-60 mg/dL is optimal for patients with coronary disease. Ideally, triglycerides should be below 120 mg/dL. Although LDL-C is still the primary target of treatment, reducing the levels of VLDL and IDL also is important. Calculation of non-HDL cholesterol provides a means of assessing levels of all the lipoproteins in the VLDL to LDL cascade. Differentiation of the disorders requires identification of the lipoproteins involved (Table 35\u20131). Diagnosis of a primary disorder usually requires further clinical and TABLE 35\u20131 The primary hyperlipoproteinemias and their treatment."
        },
        {
            "id": "Pharmacology_Katzung_3866",
            "title": "Pharmacology_Katzung",
            "content": "TABLE 35\u20132 Secondary causes of hyperlipoproteinemia. Hypertriglyceridemia is associated with increased risk of coronary disease. Chylomicrons, VLDL, and IDL are found in atherosclerotic plaques. These patients tend to have cholesterol-rich VLDL of small particle diameter and small, dense LDL. Hypertriglyceridemic patients with coronary disease or risk equivalents should be treated aggressively. Patients with triglycerides above 700 mg/dL should be treated to prevent acute pancreatitis because the LPL clearance mechanism is saturated at about this level."
        },
        {
            "id": "InternalMed_Harrison_19011",
            "title": "InternalMed_Harrison",
            "content": "cast doubt on low HDL as a causal risk factor for atherosclerotic events. Weight loss and physical activity can raise HDL, and these lifestyle measures merit universal adoption (Table 291e-3). Nicotinic acid, particularly in combination with statins, can robustly raise HDL, but clinical trial data do not support the effectiveness of nicotinic acid in cardiovascular risk reduction. Agonists of nuclear receptors provide another potential avenue for raising HDL levels. Yet patients treated with peroxisome proliferator\u2013activated receptors alpha and gamma (PPAR-\u03b1 and -\u03b3) agonists have not consistently shown improved cardiovascular outcomes, and at least some PPAR agonists have been associated with worsened cardiovascular outcomes. Other agents in clinical development raise HDL levels by inhibiting cholesteryl ester transfer protein (CETP). Two such agents have undergone large-scale clinical evaluation and have not shown efficacy in improving cardiovascular outcomes. Clinical studies"
        },
        {
            "id": "Pathology_Robbins_2259",
            "title": "Pathology_Robbins",
            "content": "Apolipoprotein(a) is homologous to plasminogen, suggesting a potential link between thrombogenesis and circulating molecules that can drive atherosclerosis. Elevated levels of procoagulants are potent predictors of risk for major cardiovascular events including myocardial infarction and stroke. Excessive activation of thrombin, which you may recall can initiate inflammation through cleavage of protease-activated receptors (PARs; Chapter 4) on leukocytes, endothelium, and other cells, may be particularly atherogenic."
        },
        {
            "id": "Pharmacology_Katzung_3860",
            "title": "Pharmacology_Katzung",
            "content": "E. High-Density Lipoproteins The apoproteins of HDL are secreted largely by the liver and intestine. Much of the lipid comes from the surface monolayers of endothelium Lipoprotein lipase FFA HDL VLDL remnant B-100 ApoC VLDL ApoE HDL LDL Peripheral cell Cholesterol Cholesteryl estersLysosome Acetyl-CoA HMG-CoA reductase Lysosome Cholesterol Mevalonic acid ApoB, ApoE, ApoC RER Golgi vesicle LDL receptor * * Cholesterol biosynthetic pathway"
        },
        {
            "id": "Biochemistry_Lippincott_845",
            "title": "Biochemistry_Lippinco",
            "content": "A. Chylomicrons B. High-density lipoproteins C. Intermediate-density lipoproteins D. Low-density lipoproteins E. Very-low-density lipoproteins Correct answer = A. The milky appearance of her plasma was a result of triacylglycerol-rich chylomicrons. Because 5 a.m. is presumably several hours after her evening meal, the patient must have difficulty degrading these lipoprotein particles. Intermediate-, low-, and high-density lipoproteins contain primarily cholesteryl esters, and, if one or more of these particles was elevated, it would cause hypercholesterolemia. Very-low-density lipoproteins do not cause the described milky appearance of plasma. 8.4. Which one of the following proteins is most likely to be deficient in this patient? A. Apolipoprotein A-I B. Apolipoprotein B-48 C. Apolipoprotein C-II D. Cholesteryl ester transfer protein E. Microsomal triglyceride transfer protein"
        },
        {
            "id": "Biochemistry_Lippincott_798",
            "title": "Biochemistry_Lippinco",
            "content": "Release from the liver: VLDL are secreted directly into the blood by the liver as nascent particles containing apo B-100. They must obtain apo CII and apo E from circulating HDL (see Fig. 18.17). As with chylomicrons, apo C-II is required for activation of LPL. [Note: Abetalipoproteinemia is a rare hypolipoproteinemia caused by a defect in MTP, leading to an inability to load apo B with lipid. Consequently, few VLDL or chylomicrons are formed, and TAG accumulates in the liver and intestine. Absorption of fat-soluble vitamins is decreased. LDL are low.] 2."
        },
        {
            "id": "InternalMed_Harrison_12175",
            "title": "InternalMed_Harrison",
            "content": "Several purified surface proteins have been evaluated in phase 1 clinical trials but have not yet been developed further because of antigenic variability or poor immunogenicity (e.g., transferrin-binding FIGURE 180-7 Illustration of meningococcal outer-membrane vesicle containing outer-membrane structures. proteins, neisserial surface protein A). Other vaccine candidates have been identified since sequencing of the meningococcal genome. A combination vaccine that includes the New Zealand OMV vaccine and three recombinant proteins (neisserial adhesin A, factor H\u2013binding protein, and neisserial heparin-binding antigen) is immunogenic in infancy and has been licensed for use in Europe and Australia. Recommendations for its use are pending. Finally, a highly immunogenic vaccine based on two variants of the lipoprotein factor H\u2013binding protein is undergoing clinical evaluation"
        },
        {
            "id": "Biochemistry_Lippincott_846",
            "title": "Biochemistry_Lippinco",
            "content": "A. Apolipoprotein A-I B. Apolipoprotein B-48 C. Apolipoprotein C-II D. Cholesteryl ester transfer protein E. Microsomal triglyceride transfer protein Correct answer = C. The triacylglycerol (TAG) in chylomicrons is degraded by endothelial lipoprotein lipase (LPL), which requires apolipoprotein (apo) C-II as a coenzyme. Deficiency of LPL or apo C-II results in decreased ability to degrade chylomicrons to their remnants, which get cleared (via apo E) by liver receptors. Apo A-I is the coenzyme for lecithin:cholesterol acyltransferase; apo B-48 is the characteristic structural protein of chylomicrons; cholesteryl ester transfer protein catalyzes the cholesteryl ester\u2013TAG exchange between high-density and very-low-density lipoproteins (VLDL); and microsomal triglyceride transfer protein is involved in the formation, not degradation, of chylomicrons (and VLDL). 8.5. Complete the table below for an individual with classic 21-\u03b1-hydroxylase deficiency relative to a normal individual."
        },
        {
            "id": "Pharmacology_Katzung_3923",
            "title": "Pharmacology_Katzung",
            "content": "Mipomersen is an antisense oligonucleotide that targets apo B-100, mainly in the liver. It is important to note that the apo B-100 gene is also transcribed in the retina and in cardiomyocytes. Subcutaneous injections of mipomersen reduce levels of LDL and Lp(a). Mild to moderate injection site reactions and flu-like symptoms can occur. The drug is available only for use in homozygous familial hypercholesterolemia through a restricted (REMS) program."
        },
        {
            "id": "InternalMed_Harrison_28232",
            "title": "InternalMed_Harrison",
            "content": "The majority of patients with low HDL-C have some combination of genetic predisposition and secondary factors. Variants in dozens of genes have been shown to influence HDL-C levels. Even more important quantitatively, obesity and insulin resistance have strong suppressive effects on HDL-C, and low HDL-C in these conditions is widely observed. Furthermore, the vast majority of patients with elevated TGs have reduced levels of HDL-C. Most patients with low HDL-C who have been studied in detail have accelerated catabolism of HDL and its associated apoA-I as the physiologic basis for the low HDL C. Importantly, although HDL-C remains an important biomarker for assessing cardiovascular risk, it is not currently a direct target of intervention for raising the level in order to reduce cardiovascular risk. Certain therapeutic approaches in clinical development, such as inhibitors of CETP (see below), have the potential to change this paradigm."
        },
        {
            "id": "Pharmacology_Katzung_6190",
            "title": "Pharmacology_Katzung",
            "content": "Alirocumab and Evolocumab are anti-cholesterol Mabs (see Chapter 35). They lower LDL levels by blocking proprotein convertase subtilisin/kexin type 9 (PCSK9) from binding to LDL receptors (LDRL) and causing LDL receptor degradation. Therefore, these Mabs have the effect of increasing LDLR on hepatocytes, which lowers LDL levels in circulation. They are approved as an adjunct to diet and maximally tolerated statin therapy in adults with homoor heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C."
        },
        {
            "id": "Pharmacology_Katzung_3934",
            "title": "Pharmacology_Katzung",
            "content": "Atorvastatin Generic, Lipitor Cholestyramine Generic, Questran, Prevalite Colestipol Generic, Colestid Ezetimibe Generic, Zetia Fenofibrate Generic, Tricor, Antara, Lofibra Fluvastatin Generic, Lescol, Lescol XL Gemfibrozil Generic, Lopid Lovastatin Generic, Mevacor, Altoprev Niacin, nicotinic acid, vitamin B3 Generic only Pravastatin Generic, Pravachol Rosuvastatin Generic, Crestor Simvastatin Generic, Zocor Afshar M, Thanassoulis G: Lipoprotein(a): new insights from modern genomics. Curr Opin Lipidol 2017;28:170. Ballantyne CM et al: Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: Results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol 2013;62:1154."
        },
        {
            "id": "InternalMed_Harrison_18955",
            "title": "InternalMed_Harrison",
            "content": "An integrated view of experimental results in animals and studies of human atherosclerosis suggests that the \u201cfatty streak\u201d represents the initial lesion of atherosclerosis. These early lesions most often seem to arise from focal increases in the content of lipoproteins within regions of the intima. In particular, the fraction of lipoproteins related to low-density lipoprotein (LDL) that bear apolipoprotein B appear causally related to atherosclerosis. This accumulation of lipoprotein particles may not result simply from increased permeability, or CHAPTER 291e The Pathogenesis, Prevention, and Treatment of Atherosclerosis Monocyte"
        }
    ],
    "scores": [
        0.027634865134865134,
        0.02729706351691945,
        0.02719326212869972,
        0.025083638500836385,
        0.02465242267613809,
        0.023153060450808574,
        0.021682261215616457,
        0.021231527093596058,
        0.020894190360113755,
        0.0196078431372549,
        0.018957771787960466,
        0.018883049790683174,
        0.018523636487708346,
        0.018447998646018447,
        0.017786561264822136,
        0.01778093883357041,
        0.016758241758241758,
        0.01639784946236559,
        0.01633986928104575,
        0.016234616391725583,
        0.01579520697167756,
        0.015550707613134195,
        0.015281423155438904,
        0.01526510212950891,
        0.01525900900900901,
        0.01518288474810214,
        0.014973262032085561,
        0.014781555847038642,
        0.014554659072931499,
        0.014495798319327732,
        0.014387464387464386,
        0.014154704944178628
    ]
}